AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02054442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: We will perform a randomized phase II study to investigate in first line if the addition of cetuximab to MTX is beneficial, i.e. improvement in the PFS, for the patient.
Study NCT02054442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT02054442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study NCT01330472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xanax XR tablets 3 mg (sourced from Caugus)
Description: Tablets, 3 mg, single dose
Study NCT01330472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanax XR tablets 3 mg (sourced from Barceloneta)
Description: Tablets, 3 mg, single dose
Study NCT02362464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine
Description: dose of 20 x 10\^6 viable cells multiepitope TARP dendritic cell vaccine given intradermally at weeks 3, 6, 9, 12, 15 and 24.
Study NCT02392572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt/ERK Inhibitor ONC201
Description: Given PO
Study NCT01862224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168
Description: JNJ-38518168 30 mg once daily, Week 0 to Week 52.
Study NCT01862224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-38518168
Description: JNJ-38518168 30 mg once daily, Week 0 to Week 52.
Study NCT03924570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPASS
Description: IPASS is behavioral package to improve transitions of care by providing a framework to hands off.
Study NCT03143270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: All participants will receive at a flat dose of 240 mg IV q 12 weeks for up to one year. In cohort 1, participants will begin nivolumab two weeks (+/- 5 days) after deb-TACE every two weeks. In cohort 2, participants will begin nivolumab every 2 weeks for 1 year and undergo deb-TACE 4 weeks after the initiation of nivolumab (+/- 5 day). Nivolumab will not be dosed on the day of embolization in this cohort. In cohort 3, nivolumab will be dosed every two weeks starting 4 weeks (+/- 5 days) prior to deb-TACE and continue every 2 weeks for up to one year. Nivolumab will be dosed on the day of embolization in this cohort. It will be administered before the deb-TACE procedure.
Study NCT01862224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo once daily (Week 0 to Week 12).
Study NCT01862224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: All participants will continue receiving methotrexate up to Week 12. After Week 12, the dose of methotrexate may be adjusted as per Investigator's discretion.
Study NCT01862224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: All participants will continue receiving methotrexate up to Week 12. After Week 12, the dose of methotrexate may be adjusted as per Investigator's discretion.
Study NCT03655704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apabetalone
Description: A 4-week pre-treatment phase will allow ensuring that patients are on stable doses of medication. Patients will be given doses of apabetalone 100mg BID for 16 weeks. Patients will be regularly followed (Fig.1). At baseline and week 16, a cardiac catheterization and MRI will assess changes in pulmonary hemodynamics and RV function.
Study NCT00810654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aspergillus niger prolyl endoprotease
Description: 160 PPU daily for 2 weeks
Study NCT00810654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03082040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based breathing training
Description: The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks. Participants in the control condition will participate the same breathing training after a four-week waiting list period.
Study NCT00329771 — intervention group
Intervention type: OTHER
Intervention: No intervention: We are testing for the presence of allodynia
Description: We are testing for the presence of abnormal sensation (allodynia) during a migraine attack.
Study NCT03082040 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: home-based breathing training
Description: The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks. Participants in the control condition will participate the same breathing training after a four-week waiting list period.
Study NCT03195270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FDG
Description: 10 mCi of \[18F\]FDG via the antecubital vein in a bolus injection
Study NCT03195270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: PET/MRI hybrid scanner used as diagnostic device
Study NCT00927277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia(R) LipoLASER PL; Erchonia(R) EML Laser
Description: The Erchonia(R) EML Laser is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated.
Study NCT00927277 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Erchonia(R) LipoLASER PL
Study NCT03722732 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreaticoduodenectomy
Description: pancreaticoduodenectomy either laparoscopically or open will be done
Study NCT03044691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ResearchACTS software
Description: screen patients for tobacco and nicotine product use (using the anticipate and ask components of the 6As) by having youth complete a tobacco and nicotine use screening tool using the ResearchACTS software.
Study NCT01708369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Orange juice administered 15 minutes before subjects take oseltamivir or aspirin
Study NCT01259219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycobutin
Description: Indication and Usage:~Mycobutin capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV Infection.~Dosage and Directions for use:~Mycobutin cab be administred as a single daily dose, independent of meals. In all cases Mycobutin is to be administred in combination regimens.~Identification:~Red-brown, self locking, hard gelatin capsule, size 0, containing a violet powder.
Study NCT04449822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emergency surgery
Description: Surgical decompression with colostomy with or without resection and eventual re-anastomosis.
Study NCT04449822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonic stenting
Description: The colonic stent placement to relieve the colonic obstruction.
Study NCT01708369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Ethanol will be mixed with orange juice and subjects will drink the mixture 15 minutes before receiving oseltamivir or aspirin
Study NCT03958305 — intervention group
Intervention type: PROCEDURE
Intervention: RADICAL HYSTERECTOMY
Description: Radical hysterectomy is an operation done to treat some cancers of the cervix. The surgeon takes out the uterus and the ligaments (tissue fibers) that hold it in place. The cervix and an inch or 2 of the vagina around the cervix are also removed.
Study NCT02379975 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical Periodontal Therapy
Study NCT01708369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir 150 mg orally
Study NCT02379975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical Periodontal Therapy
Study NCT03374722 — intervention group
Intervention type: DRUG
Intervention: Opioids
Description: Mechanically ventilated critically ill patients who receive continuous opioid infusion for more than 24 hours will be observed for withdrawal symptoms when rate of opioid infusion is disrupted or decreased
Study NCT05128799 — intervention group
Intervention type: OTHER
Intervention: 3 Wishes Program (3WP)
Description: The 3 Wishes Program (3WP) is a palliative care intervention in which small wishes are implemented by healthcare workers (HCWs) in an effort to improve the EOL experience for dying patients and their families. Examples of wishes include playing the patient's favorite music, providing a non-hospital blanket, orchestrating a final date night, decorating a patient's room to reflect their identify, and providing grieving family members with keepsakes such as thumbprint keychains, framed EKG mementos, or word clouds.
Study NCT01708369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir 150 mg orally
Study NCT00442559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Montelukast 4/5 mg tablet (oral chewable), once daily, 12 weeks to up to 12 months
Study NCT01708369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 650 mg orally will be given
Study NCT01708369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 650 mg orally will be given
Study NCT00700466 — intervention group
Intervention type: DRUG
Intervention: i.v. beta-blocker infusion (metoprolol)
Description: A beta-blocker (metoprolol) will be infused for treatment of hypertension and/or tachycardia prior to induction of anesthesia aiming at decrease of blood pressure and heart rate to normal limits
Study NCT01751490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: physiotherapy
Study NCT01751490 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: shoulder stabilisation surgery
Description: arthroscopic stabilisation surgery
Study NCT03085940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 400mg once daily initially
Study NCT02378545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: On the Hyperoxia arm: Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose.~On the Normoxia arm: In many cases oxygen will not be administered. If required the minimum percentage required to reach the target saturations will be administered. In a majority of cases this will be via a venturi mask.
Study NCT05209685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise on the lower extremities
Description: Resistance exercise mainly on the lower extremities will be executed by carrying weight according to each participant's tolerance while performing certain movements, such as side step-up, sit-to-stand, and tip-toe-standing.
Study NCT05209685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise on the lower extremities with blood flow restriction
Description: Blood flow restriction on the thigh of the dominant leg will be used in combination with resistance exercise.
Study NCT04366440 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Order set review and modification with facilitation
Description: The antimicrobial stewardship program will receive facilitation training to aid in reviewing and changing order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
Study NCT04366440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Order set review and modification
Description: The antimicrobial stewardship program will work to eliminate unnecessary post-operative antibiotics by reviewing and changing order sets of clean or clean-contaminated procedures.
Study NCT00806546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP101
Description: NP101 study patch four hour application
Study NCT02825303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Workplace consisting of two height-adjustable desks
Description: Desk arrangements: self-determined by the participants Desk equipment: depending on pre-intervention condition - 1 or 2 screens per desk Build-up: one day prior to the intervention period at the location of the workplace Adjustment: together with the study leader
Study NCT02751177 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA
Description: Mutation in plasma DNA vs tumor tissue
Study NCT01071512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tysabri
Description: Infuse TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP. Tysabri will be infused every four weeks.
Study NCT04275596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2QR complex
Description: Application of topical gel containing 2QR complex on the anal wound until complete wound healing
Study NCT04275596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Application of topical placebo on the anal wound until complete wound healing
Study NCT01664013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nuronox
Description: Reconstituted Neuronox® is injected at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.Actual dose and injection site should be adjusted individually considering the muscle mass, degree of spasticity, body weight, and response to any previous botulinum toxin injections.
Study NCT02102633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Dabigatran 150 mg orally
Study NCT03085940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02751658 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: mouth swab
Description: Levy to make inside of the mouth with a swab on the day of admission to hospital and the day of release at the patients in the Otorhinolaryngology
Study NCT00442559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled corticosteroid
Description: Inhaled corticosteroid solution, 1-4 puffs daily, 12 weeks to up to 12 months
Study NCT04009109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Induction and Maintenance
Study NCT04009109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Induction and Only Maintenance Arm B
Study NCT01333501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: 0.5 mg in capsules for oral administration once daily
Study NCT01333501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta 1b
Description: 250 μg injected s.c. every other day
Study NCT02405624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure
Description: CPAP training for muscle strength
Study NCT04276532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node sampling (SLN)
Description: Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus sentinel lymph node sampling (SLN).~1. The principles of surgery procedures and post-operative adjuvant therapies will follow the latest NCCN guidelines；~2. Surgery carried out by laparotomy, laparoscope, or robotic surgery are accepted；~3. Colored dyes including indocyanine green (ICG) (preferred), methylene blue, carbon nanotube for sentinel lymph node are accepted.
Study NCT04276532 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pelvic lymphonodectomy (PLN)
Description: Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus pelvic lymphonodectomy (PLN) with para-aortic sampling
Study NCT01574924 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Description: There are no interventions in this observational study.
Study NCT00852657 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tendon repair with acromioplasty
Description: Open or mini-open tendon repair in combination with an acromioplasty and eventually a tenodesis of the long head of the biceps
Study NCT00852657 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: According to a rehabilitation program which was established prior to study start.
Study NCT04098991 — intervention group
Intervention type: DRUG
Intervention: Levothyroxine
Description: All participants will be treated for their hypothyroidism according to the standard of care as reflected in recent guidelines from the American Thyroid Association.
Study NCT02426359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q301 Cream
Study NCT04009109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab Injection
Description: Induction and Only Maintenance Arm B
Study NCT04009109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction and Only Maintenance Arm B
Study NCT01916525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise based cardiac rehabilitation
Description: The cost-effectiveness between the exercise training vs. control groups
Study NCT00531167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of lamivudine+adefovir vs entecavir
Description: Lamivudine 100 mg/day, Adefovir 10 mg/day, Entecavir 0.5 mg/day
Study NCT00531167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combination of lamivudine+adefovir vs entecavir
Description: Lamivudine 100 mg/day, Adefovir 10 mg/day, Entecavir 0.5 mg/day
Study NCT05224388 — intervention group
Intervention type: DRUG
Intervention: Enoxaparin
Description: Use of enoxaparin in either prophylactic dose regimen or therapeutic dose regimen
Study NCT05224388 — intervention group
Intervention type: DRUG
Intervention: Heparin
Description: Use of heparin in either prophylactic dose regimen or therapeutic dose regimen
Study NCT01508117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5 mg twice daily starting 21 days after resection and continuing until progression or unacceptable toxicity
Study NCT01508117 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 45 Gy in 15 fractions starting after 28 days of Axitinib monotherapy
Study NCT02426359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03175068 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: CBT works by changing people's attitudes and their behavior by focusing on the thoughts, images, beliefs and attitudes that are held (a person's cognitive processes) and how these processes relate to the way a person behaves, as a way of dealing with emotional problems.
Study NCT01979211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m2 IV over 120 minutes week 1; 250 mg/m2 IV over 60 minutes weekly weeks 2-7
Study NCT01979211 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation Therapy 60-66 Gy in 2 Gy fractions starting week 2 of Cetuximab
Study NCT03277391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane block
Description: SPB realized under ultrasound guidance. Infiltration of local anesthetic (bolus then infusion through a multi-holed catheter) is realized under the serratus anterior muscle at a level situated around the 5th to 6th intercostal space on the anterior axillary lign, in order to anesthetize the cutaneous lateral branches of the intercostal nerves, with a first ropivacaine 0,375% bolus (0,4ml/kg), followed by an infusion of ropivacaine 0,2% at a 10ml/hr rate, through a multi-holed catheter, for a duration of 24 hours.
Study NCT03277391 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: patient-controlled analgesia
Description: Each patient controls his analgesia with an IV bolus of 2mg of morphine every 10 minutes if needed, with a maximum of 20mg every 4 hours.
Study NCT03175068 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ST
Description: Treatment designed to improve, reinforce, or sustain a patient's physiological well-being or psychological self-esteem and self-reliance
Study NCT00981331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subtalar joint manipulation
Description: The intervention is defined as a toggle-recoil, high-velocity, low-amplitude subtalar joint manipulation.
Study NCT00981331 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham subtalar joint manipulation
Description: The sham manipulation is conducted by placing the ankle in a non-manipulative position, and the operator simply engages the toggle board to simulate the audible noise of the toggle board dropping. No force or thrust is applied to the ankle.
Study NCT04943601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: action observation therapy
Description: The participants will be three meters from the screen onto which the videos will be projected. The initial posture will vary depending on each movement, lying down, sitting, or standing and ensuring a clear field of vision. The sessions will be performed in groups of three to four patients